← Eichor
Study identifier: NCT06909240 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DVT-Cph RCT)

Condition: Deep Vein Thrombosis (DVT)  ·  Sponsor: Hvidovre University Hospital

PhaseNA
Planned participants152
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The DVT-Cph RCT aims to investigate: 1. if progressive gait training in combination with standard care is superior to standard care on quality of life in patients with first time lower extremity deep venous thrombosis (clinical effectiveness part). 2. the association between progressive gait training and disease progression, late complications such as post throbotic syndrome, and severity of venous thromboembolism conditions in patients with first time lower extremity deep venous thrombosis (mechanistic part).

This description comes directly from the study's public registry record.

Talk to the study team

Mette Merete Pedersen, Ph.D.  ·  +4538623350  ·  mette.merete.pedersen@regionh.dk

Ove Andersen, M.D., Ph.D.  ·  +4529333262  ·  ove.andersen@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Hvidovre University HospitalHvidovre, Capital Region, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06909240